Entero Healthcare Solutions Ltd

Entero Healthcar Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Entero Healthcare Solutions Ltd

₹ 1,402 -1.21%
03 Jan - close price
enterohealthcare.com BSE: 544122 NSE: ENTERO
About

Incorporated in 2018, Entero Healthcare
Solutions Ltd is in the business of distribution
and marketing of pharmaceutical and surgical products and allied services[1]

Key Points

Business Overview:[1]
EHSL, a leading Healthcare Supply Chain Solutions Specialist, ranks among India’s top three healthcare product distributors by revenue, offering demand fulfillment and generation solutions to manufacturers.

Website BSE NSE
  • Market Cap ₹ 6,098 Cr.
  • Current Price ₹ 1,402
  • High / Low ₹ 1,584 / 970
  • Stock P/E 81.9
  • Book Value ₹ 383
  • Dividend Yield 0.00 %
  • ROCE 3.99 %
  • ROE 4.97 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Stock is trading at 3.67 times its book value
  • Earnings include an other income of Rs.120 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Retail Industry: Trading

Part of Nifty Microcap 250 BSE SmallCap BSE IPO BSE Allcap BSE Consumer Discretionary

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
55 50 61 74 77 107 122 113
64 58 69 83 85 116 124 119
Operating Profit -10 -7 -8 -9 -8 -9 -2 -6
OPM % -18% -15% -12% -12% -11% -9% -2% -5%
14 14 15 17 16 42 32 29
Interest 3 3 5 7 5 6 0 0
Depreciation 2 3 2 2 2 2 2 2
Profit before tax -1 1 0 -2 1 26 28 20
Tax % 0% 0% -2,838% -6% -36% -44% 25% 24%
-1 1 2 -2 1 37 21 15
EPS in Rs -2.38 1.56 5.74 -1.33 0.59 8.57 4.80 3.52
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
105 137 178 318 418
137 191 222 353 444
Operating Profit -32 -54 -44 -34 -26
OPM % -30% -39% -25% -11% -6%
23 27 53 90 120
Interest 2 5 11 22 11
Depreciation 7 9 10 9 8
Profit before tax -18 -41 -12 24 75
Tax % 0% 0% 0% -58%
-18 -41 -12 38 74
EPS in Rs -1,811.38 -106.10 -30.31 8.84 17.48
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 45%
TTM: 74%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 60%
TTM: 62133%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 0.10 4 4 43 43
Reserves -31 -72 -84 1,583 1,620
540 674 775 18 16
23 47 68 125 105
Total Liabilities 533 654 764 1,769 1,785
50 51 41 34 31
CWIP 2 0 0 0 0
Investments 39 39 41 41 228
442 563 682 1,694 1,525
Total Assets 533 654 764 1,769 1,785

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
-68 -45 -57 -76
-7 -69 -58 -763
76 127 91 926
Net Cash Flow 0 14 -24 87

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 107 139 153 130
Inventory Days 177 103 68 65
Days Payable 48 99 132 88
Cash Conversion Cycle 236 143 89 107
Working Capital Days 1,210 1,123 1,086 855
ROCE % -6% -0% 4%

Shareholding Pattern

Numbers in percentages

2 Recently
Mar 2024Jun 2024Sep 2024
52.44% 52.44% 52.44%
23.30% 23.32% 23.82%
2.28% 2.06% 7.73%
21.99% 22.18% 16.02%
No. of Shareholders 80,86466,40036,767

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls